Study details
Enrolling now
Dupixent and Narrowband UVB for Atopic Dermatitis
Psoriasis Treatment Center of Central New Jersey
NCT IDNCT05285839ClinicalTrials.gov data as of Apr 2026
Phase
Phase 4
Target enrollment
40
Study length
about 2.7 years
Ages
18+
Locations
1 site in NJ
About this study
This trial is testing a treatment with Dupixent combined with narrowband UVB phototherapy to see if it helps people with atopic dermatitis. The treatment involves taking Dupixent, along with light therapy three times per week for a period of time, followed by just Dupixent alone for another period of time.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Dupixent
PhasePhase 4
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low4%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Body systems
Dermatology